CTOs on the Move

Pascal Biosciences

www.pascalbiosciences.com

 
Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company`s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Optherion Inc

Optherion Inc is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A W Research Laboratories

A W Research Laboratories is a Brainerd, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forum Pharmaceuticals

FORUM Pharmaceuticals Inc. (“FORUM Pharmaceuticals” or “FORUM”) is dedicated to developing transformative medicines to restore the minds of people with serious brain disease, empowering them to preserve their identity, dignity and the essence of what makes us human. The Company`s diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM is privately owned and based in Waltham, Mass.

Interleuken Genetics

Interleuken Genetics is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.